Infinity Pharmaceuticals, Inc.
INFIQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 2.57M | 2.67M | 2.59M | 2.50M | 2.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.57M | 2.67M | 2.59M | 2.50M | 2.22M |
| Cost of Revenue | 28.63M | 30.89M | 33.97M | 35.37M | 34.61M |
| Gross Profit | -26.06M | -28.21M | -31.38M | -32.87M | -32.39M |
| SG&A Expenses | 15.99M | 15.73M | 13.46M | 13.94M | 14.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.62M | 46.62M | 47.44M | 49.31M | 48.89M |
| Operating Income | -42.05M | -43.94M | -44.84M | -46.81M | -46.68M |
| Income Before Tax | -40.95M | -42.98M | -44.37M | -46.79M | -46.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.95 | -42.98 | -44.37 | -46.79 | -46.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.95M | -42.98M | -44.37M | -46.79M | -46.79M |
| EBIT | -42.05M | -43.94M | -44.84M | -46.81M | -46.68M |
| EBITDA | -41.62M | -43.50M | -44.39M | -46.33M | -46.19M |
| EPS Basic | -0.46 | -0.48 | -0.50 | -0.52 | -0.53 |
| Normalized Basic EPS | -0.29 | -0.30 | -0.31 | -0.33 | -0.33 |
| EPS Diluted | -0.46 | -0.48 | -0.50 | -0.53 | -0.53 |
| Normalized Diluted EPS | -0.29 | -0.30 | -0.31 | -0.33 | -0.33 |
| Average Basic Shares Outstanding | 358.05M | 357.32M | 357.07M | 356.80M | 356.17M |
| Average Diluted Shares Outstanding | 358.05M | 357.32M | 357.07M | 356.80M | 356.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |